Permira creates major blood plasma products player with Kedrion, BPL acquisitions

Global private equity major Permira has completed the joint acquisition and combination of Kedrion and BPL, creating a major player for medicinal products derived from human blood plasma.

The Abu Dhabi Investment Authority and Ampersand Capital Partners are co-investors in the deal.

The business will have a combined US plasma collection footprint of nearly 75 centres, with a portfolio of 37 products reaching over 100 countries.

It is expected to generate 60% of revenue in the US market with 10 marketed products, and is also establishing a presence in the Chinese market through its recent distribution agreement for Albuminex.

Silvia Oteri, partner and global head of healthcare at Permira, said, “We are excited for this next phase of building a leading rare disease specialist platform that will deliver critical solutions to those in need around the world and with a deep commitment to its donors.”

Permira was said to have hit €16bn for its new flagship buyout fund in July, beating its target at first close.

The firm picked up €11bn for the final close of its last flasghip fundraise in 2019, one of the biggest euro-denominated buyout funds ever raised at the time.

Recent deals from Permira include agreed to take customer engagement software company Zendesk private in partnership with Hellman & Friedman at a valuation of $10.2bn.

It also sold healthcare technology management services provider Althea Group in May.

Source: Alt Assets